Anthropic announced it will run its own preclinical drug-discovery programs for neglected and rare diseases and launched Claude Science, an AI workbench for researchers. The company has not named specific diseases or detailed how it would bring candidates to market.
Healthcare AI companies are making bold claims, but many have not brought treatments to market. One article said human testing remains the key measure, citing trial timelines, costs, and current programs.
Novartis chief executive Vas Narasimhan has joined Anthropic’s board. The appointment adds a pharma executive as Anthropic expands into drug discovery and launches Claude for Life Sciences.
